# Tremelimumab

## Imjudo inj 300mg/15mL

| TAH Drug Code      | [IIMJU](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IIMJU)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Hepatocellular Carcinoma In combination with durvalumab， it is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Hepatocellular carcinoma， unresectable: Patients >=30 kg: IV: 300 mg on day 1 of cycle 1 only (in combination with durvalumab)， followed by durvalumab monotherapy until disease progression or unacceptable toxicity. Patients <30 kg: IV: 4 mg/kg on day 1 of cycle 1 only (in combination with durvalumab)， followed by durvalumab monotherapy until disease progression or unacceptable toxicity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Hypersensitivity to tremelimumab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | >10%: Dermatologic: Pruritus (23%)， skin rash (<=32%; including dermatitis) Endocrine & metabolic: Decreased serum albumin (31%)， decreased serum calcium (34%)， decreased serum sodium (46%)， hypothyroidism (11% to 14%)， increased serum glucose (39%)， increased serum potassium (28%) Gastrointestinal: Abdominal pain (20%)， decreased appetite (17%)， diarrhea (<=27%; grades 3/4: <=6%)， nausea (12%) Hematologic & oncologic: Decreased hemoglobin (52%; grades 3/4: 5%) decreased platelet count (29%; grades 3/4: 2%)， leukopenia (20%; grades 3/4: <1%)， lymphocytopenia (41%; grades 3/4: 11%) Hepatic: Increased serum alanine aminotransferase (56%)， increased serum alkaline phosphatase (41%)， increased serum aspartate aminotransferase (63%)， increased serum bilirubin (41%) Immunologic: Antibody development (11%; of which 40% developed neutralizing antibodies) Nervous system: Fatigue (26%) Neuromuscular & skeletal: Musculoskeletal pain (22%) Renal: Increased serum creatinine (21%) Miscellaneous: Fever (13%) 1% to 10%: Endocrine & metabolic: Adrenocortical insufficiency (2%)， hyperthyroidism (5%)， hypophysitis (?1%)， pituitary insufficiency (?1%)， thyroiditis (2%) Gastrointestinal: Colitis (?6%)， pancreatitis (2%) Hematologic & oncologic: Hemorrhage (serious: 6%) Hepatic: Hepatitis (8%) Hypersensitivity: Infusion-related reaction (3%) Infection: Sepsis (2%) Nervous system: Insomnia (10%) Renal: Acute kidney injury (1%)， nephritis (1%) Respiratory: Pneumonia (serious: 2%)， pneumonitis (1%) <1%: Endocrine & metabolic: Hyperglycemia |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tremelimumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

